TITLE

EXPANDED HUMAN TESTING OF NASAL FLU VACCINE BEGINS

PUB. DATE
July 2001
SOURCE
Worldwide Biotech;Jul2001, Vol. 13 Issue 7, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Announces the start of the expanded human safety and immunogenecity testing of the intranasal influenza vaccine from ID Biomedical Corporation.
ACCESSION #
4764381

 

Related Articles

  • Canadian company to develop mock pandemic vaccine. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;3/1/2005, Vol. 172 Issue 5, p623 

    Focuses on a mock pandemic vaccine being developed by Vancouver-based ID Biomedical Corp. to protect people against H5N1 influenza in British Columbia. Utilization of reverse genetics technology; Requirements for the phase II clinical trials; Comment from Michele Roy, spokesperson for ID...

  • Chiron's manufacturing misfortunes boost competitors. Sheridan, Cormac // Nature Biotechnology;Oct2005, Vol. 23 Issue 10, p1191 

    The article focuses on problems faced by Chiron Corp., the world's second largest flu vaccine supplier. Chiron's ongoing problems in influenza vaccine production have raised serious questions about the Emeryville, California company's future ability to compete in this particular segment of the...

  • Phase II data shows strong immunogenicity for ID Biomedical's FluINsure.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p7 

    Focuses on the clinical trials for FlulNsure, an intranasal, non-live, influenza vaccine developed by ID Biomedical Corp. Patients enrolled in the study; Presentation of the clinical study of FlulNsure; Evaluation on the efficacy of the influenza vaccine.

  • GSK catches flu shot.  // Chemical Market Reporter;9/12/2005, Vol. 268 Issue 8, p5 

    Reports that United States-based pharmaceutical firm Glaxosmithkline PLC continued its aggressive pursuit of a top slot in the flu vaccines arena with its bid for Vancouver, British Columbia-based ID Biomedical Corp. Worth of the bid; Benefit of the acquisition to Glaxosmithkline;...

  • Industry News Headlines April 15, 2004 - May 14, 2004.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p20 

    Reports developments in the biotechnology industry as of April 2004. Acquisition of Shire Pharmaceuticals by ID Biomedical Corp.; Details on the lawsuit filed by Biota against GlaxoSmithKline PLC for failure to promote influenza drug; Sale of Zonegran, an ani-epiletic drug to Eisai Inc.

  • show case.  // Pharmacy Today;Feb2014, Vol. 20 Issue 2, p19 

    The article offers information on several drugs that were approved by the U.S. Food & Drug Administration including the H5N1 avian influenza vaccine from ID Biomedical Corp., the Raltegravir from Merck, and the Telmisartan immediate-release tablet angiotension II receptor blocker from Actavis.

  • Infection control Update.  // Healthcare Purchasing News;Feb2005, Vol. 29 Issue 2, p26 

    Presents news briefs on the health care industry as of February 2005. Information on the safety-engineered BD Integra 1ml Retracting Tuberculin and Insulin Syringe released by Becton, Dickenson, and Company; Clearance received by ID Biomedical from the U.S. Food and Drug Administration to run a...

  • New products.  // Drug Topics;Oct2012, Vol. 156 Issue 10, p61 

    The article informs on various drugs and related products who have received approval from the Food & Drug Administration (FDA) in the U.S. It is mentioned that the FDA has approved the 2012-2013 influenza (flu) vaccine formulation of CSL Ltd., ID Biomedical Corp. and Sanofi Pasteur. Also,...

  • ID BIOMEDICAL INITIATES STREPTAVAX CLINICAL TRIAL.  // Worldwide Biotech;Sep2001, Vol. 13 Issue 9, p1 

    No abstract available.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics